Noble Financial Initiates Heron Therapeutics At Buy
Noble Financial initiated coverage on shares of Heron Therapeutics (NASDAQ: HRTX) with a Buy rating.
The target price for Heron Therapeutics is set to $18.
Heron Therapeutics shares have declined 8.26% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.
Heron Therapeutics' shares dropped 1.17% to close at $8.44 yesterday.
Latest Ratings for HRTX
|Oct 2016||Brean Capital||Assumes||Buy|
|Sep 2016||Lake Street||Assumes||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.